Apogee Therapeutics (NASDAQ: APGE) Acquired by AbbVie: Stock Downgrade and Market Impact

• Apogee Therapeutics (NASDAQ: APGE) is being acquired by AbbVie (NYSE: ABBV) for approximately $10.90 billion, with shareholders set to receive $135.11 per share.
• Following the acquisition announcement, analysts downgraded Apogee Therapeutics to a "Hold" rating, setting a new price target of $135.00.
• The market reacted strongly to the news, with Apogee Therapeutics stock surging 46.66% on high trading volume.

Apogee Therapeutics (NASDAQ: APGE) is a biotechnology company that develops treatments for immunology and respiratory diseases. Its main drug candidates include zumilokibart, an antibody for atopic dermatitis, and APG273, a therapy for asthma. The company operates in a competitive sector alongside large pharmaceutical firms like AbbVie (NYSE: ABBV).

In a significant move, AbbVie has agreed to acquire Apogee Therapeutics for approximately $10.90 billion, as highlighted by GuruFocus. This acquisition is designed to enhance AbbVie's immunology portfolio. Under the terms of the deal, Apogee Therapeutics shareholders are set to receive $135.11 per share in cash for their holdings.

Following this announcement, analyst David Hoang of Deutsche Bank downgraded Apogee Therapeutics to a "Hold" rating from "Buy" on June 22, 2026. A "Hold" rating typically suggests an analyst believes the stock will perform in line with the market, with limited potential for significant gains or losses.

A new price target of $135.00 was also set for the stock. This target is just below the acquisition offer of $135.11 per share, indicating the analyst sees the buyout price as the stock's new value. At the time, the stock was trading at $132.55, showing a potential upside of only 1.85%.

The market reacted strongly to the acquisition news, with Apogee Therapeutics' stock price surging 46.66% on a high trading volume of 61.22 million shares. In a related development, the M&A Class Action Firm, Monteverde & Associates PC, has announced an investigation into the sale, as highlighted by PR Newswire.